* Thank you to all NPD attendees who joined us in Boston in 2019*
Develop Clinically Transformative Neuropsychiatric Therapeutics
Built with thought-leaders at Sage Therapeutics, Janssen and Lundbeck the 2nd Annual Neuropsychiatric Drug Development Summit (NPD) unraveled the complexities of developing truly clinically transformative neuropsychiatric drugs.
With an emphasis on depressive disorders, this industry defining meeting
- Investigated ketamine’s effects on opioid receptors in the brain
- Deciphered which biomarkers are a predictor of patient response rate
- Shared advances in clinical trial design to overcome challenges associated with placebos
Uniting 90+ drug developers from all corners of the world, NPD is your opportunity to discuss, in depth, the challenges with preclinical models, precision medicine and target selection that have been stifling the progress of your neuropsychiatric drug development.
Register your interest for 2020 & join your peers at NPD to stride towards developing clinically transformative neuropsychiatric drugs.
Other Events in the CNS Series:
t
What previous NPD attendees had to say:
“Excellent conference with a very good and diverse set of speakers and topics”
Jim Cassella, Chief Development Officer, Concert Pharmaceuticals
“Very good conference”
Christopher Missling, President & Chief Executive Officer, Anavex Life Sciences Corp.